MA32821B1 - Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier) - Google Patents
Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier)Info
- Publication number
- MA32821B1 MA32821B1 MA33877A MA33877A MA32821B1 MA 32821 B1 MA32821 B1 MA 32821B1 MA 33877 A MA33877 A MA 33877A MA 33877 A MA33877 A MA 33877A MA 32821 B1 MA32821 B1 MA 32821B1
- Authority
- MA
- Morocco
- Prior art keywords
- vaccine
- coqueluche
- combinally
- whole cellular
- antigens
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRÉSENTE INVENTION CONCERNE UN VACCIN COMBINÉ COMPRENANT UN MÉLANGE D'ANTIGÈNES POUR LA PROTECTION CONTRE DES MALADIES TELLES QUE LA DIPHTÉRIE, LE TÉTANOS, LA COQUELUCHE (VACCIN CELLULAIRE ENTIER) ET LA POLIO. LA PRÉSENTE INVENTION CONCERNE AUSSI L'INCLUSION D'UN OU DE PLUSIEURS ANTIGÈNES DANS CE VACCIN COMBINÉ, POUR LA PROTECTION CONTRE DES INFECTIONS PAR HAEMOPHILUS INFLUENZAE, LE VIRUS DE L'HÉPATITE, ET D'AUTRES PATHOGÈNES, DE SORTE QUE L'ADMINISTRATION DE CE VACCIN PUISSE SIMULTANÉMENT IMMUNISER UN SUJET CONTRE PLUS D'UN PATHOGÈNE. CETTE INVENTION EN PARTICULIER CONCERNE UN VACCIN COMBINÉ STABLE, COMPLÈTEMENT LIQUIDE, COMPRENANT LES ANTIGÈNES TELS QUE SUSMENTIONNÉS ET LES PROCÉDÉS DE FABRICATION DE CE VACCIN.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2437DE2008 | 2008-10-24 | ||
PCT/IN2009/000599 WO2010046934A1 (fr) | 2008-10-24 | 2009-10-23 | Vaccin combiné notamment contre la coqueluche (vaccin cellulaire entier) |
Publications (1)
Publication Number | Publication Date |
---|---|
MA32821B1 true MA32821B1 (fr) | 2011-11-01 |
Family
ID=42119002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA33877A MA32821B1 (fr) | 2008-10-24 | 2011-05-20 | Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier) |
Country Status (14)
Country | Link |
---|---|
US (1) | US20110195087A1 (fr) |
EP (2) | EP2361094A4 (fr) |
JP (1) | JP2012506420A (fr) |
CN (1) | CN102196817B (fr) |
AP (1) | AP2011005700A0 (fr) |
AR (1) | AR073957A1 (fr) |
BR (1) | BRPI0920629A2 (fr) |
CA (1) | CA2741393A1 (fr) |
CL (1) | CL2011000913A1 (fr) |
CO (1) | CO6430435A2 (fr) |
MA (1) | MA32821B1 (fr) |
PE (1) | PE20100365A1 (fr) |
RU (2) | RU2504398C2 (fr) |
WO (1) | WO2010046934A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102633898B (zh) * | 2012-04-23 | 2013-11-27 | 成都欧林生物科技股份有限公司 | 一种Hib多糖与蛋白结合工艺的优化方法 |
US9849066B2 (en) | 2013-04-24 | 2017-12-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CN106075428A (zh) * | 2015-07-01 | 2016-11-09 | 北京科兴中维生物技术有限公司 | 一种免疫原性组合物及其制备方法 |
KR101864029B1 (ko) * | 2015-09-16 | 2018-06-01 | 주식회사 엘지화학 | 다회투여량 혼합 백신 조성물 |
PE20200004A1 (es) * | 2016-08-26 | 2020-01-06 | Serum Institute Of India Pvt Ltd | Composicion de vacuna multivalente novedosa |
GEP20227386B (en) | 2017-07-18 | 2022-06-10 | Serum Institute Of India Pvt Ltd | Immunogenic composition having improved stability, enhanced immunogenicity and reduced reactogenicity and process for preparation thereof |
JOP20190242A1 (ar) | 2018-10-12 | 2020-04-12 | Serum Institute Of India Pvt Ltd | تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها |
WO2020165920A1 (fr) * | 2019-02-12 | 2020-08-20 | Biological E Limited | Composition vaccinale multivalente |
WO2021176409A1 (fr) | 2020-03-05 | 2021-09-10 | Sanofi Healthcare India Private Limited | Combinaison de conservateurs pour composition de vaccin |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3097140A (en) | 1958-10-31 | 1963-07-09 | Merck & Co Inc | Preparing a mixed polio, pertussis, tetanus, and diphtheria vaccine with benzethonium chloride |
US3097142A (en) | 1960-03-30 | 1963-07-09 | Merck & Co Inc | Benzyl alcohol stabilized polio vaccines and production thereof |
DK0835663T3 (da) | 1992-05-23 | 2010-02-01 | Glaxosmithkline Biolog Sa | Kombinerede vacciner omfattende Hepatitis B overfladeantigen og andre antigener |
US6488934B1 (en) * | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
FR2734484B1 (fr) | 1995-05-24 | 1997-06-27 | Pasteur Merieux Serums Vacc | Composition vaccinale liquide et procede de fabrication |
SK283565B6 (sk) | 1996-07-02 | 2003-09-11 | Connaught Laboratories Limited | Multivalentná imunogénna kompozícia a jej použitie |
PE20020126A1 (es) | 2000-06-29 | 2002-04-27 | Smithkline Beecham Biolog | Composicion de vacuna |
KR100385711B1 (ko) | 2000-07-05 | 2003-05-27 | 녹십자백신 주식회사 | 디프테리아, 파상풍 톡소이드와 백일해균 및b형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법 |
GB0223355D0 (en) | 2002-10-08 | 2002-11-13 | Chiron Spa | Vaccine |
GB0313916D0 (en) | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
KR20030069918A (ko) | 2003-06-25 | 2003-08-27 | 주식회사 삼정산업 | 간편 조립식 파렛트 판재, 간편 조립식 파렛트 중간지지구및 간편 조립식 파렛트와 그의 제작방법 |
GB0405787D0 (en) | 2004-03-15 | 2004-04-21 | Chiron Srl | Low dose vaccines |
EP1793852A1 (fr) * | 2004-08-27 | 2007-06-13 | Panacea Biotec Ltd. | Vaccin antipoliomyélitique inactivé dérivé de la souche sabin du virus de la polio |
ES2387582T3 (es) | 2006-09-07 | 2012-09-26 | Glaxosmithkline Biologicals S.A. | Vacuna de combinación con cantidades reducidas del antígeno del virus de la polio |
-
2009
- 2009-10-22 PE PE2009001195A patent/PE20100365A1/es not_active Application Discontinuation
- 2009-10-23 AR ARP090104078A patent/AR073957A1/es unknown
- 2009-10-23 CA CA2741393A patent/CA2741393A1/fr not_active Abandoned
- 2009-10-23 EP EP09821705A patent/EP2361094A4/fr not_active Withdrawn
- 2009-10-23 BR BRPI0920629A patent/BRPI0920629A2/pt not_active Application Discontinuation
- 2009-10-23 CN CN200980142458.8A patent/CN102196817B/zh active Active
- 2009-10-23 EP EP11173119.6A patent/EP2529750A1/fr not_active Withdrawn
- 2009-10-23 US US13/125,679 patent/US20110195087A1/en not_active Abandoned
- 2009-10-23 WO PCT/IN2009/000599 patent/WO2010046934A1/fr active Application Filing
- 2009-10-23 JP JP2011532773A patent/JP2012506420A/ja not_active Withdrawn
- 2009-10-23 RU RU2011120309/15A patent/RU2504398C2/ru active
- 2009-10-23 AP AP2011005700A patent/AP2011005700A0/xx unknown
-
2011
- 2011-04-21 CL CL2011000913A patent/CL2011000913A1/es unknown
- 2011-05-20 MA MA33877A patent/MA32821B1/fr unknown
- 2011-05-24 CO CO11063984A patent/CO6430435A2/es not_active Application Discontinuation
- 2011-08-29 RU RU2011135761A patent/RU2613295C2/ru not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CL2011000913A1 (es) | 2012-01-20 |
RU2011120309A (ru) | 2012-11-27 |
CN102196817A (zh) | 2011-09-21 |
PE20100365A1 (es) | 2010-05-21 |
EP2529750A1 (fr) | 2012-12-05 |
CN102196817B (zh) | 2016-04-06 |
RU2613295C2 (ru) | 2017-03-15 |
EP2361094A4 (fr) | 2012-12-05 |
RU2504398C2 (ru) | 2014-01-20 |
AR073957A1 (es) | 2010-12-15 |
CA2741393A1 (fr) | 2010-04-29 |
RU2011135761A (ru) | 2013-03-10 |
CO6430435A2 (es) | 2012-04-30 |
BRPI0920629A2 (pt) | 2016-01-12 |
US20110195087A1 (en) | 2011-08-11 |
JP2012506420A (ja) | 2012-03-15 |
EP2361094A1 (fr) | 2011-08-31 |
AP2011005700A0 (en) | 2011-06-30 |
WO2010046934A1 (fr) | 2010-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA32821B1 (fr) | Vaccin combine notamment contre la coqueluche (vaccin cellulaire entier) | |
ter Borg et al. | Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: relation to treatment response | |
MY141025A (en) | Dose forms | |
WO2008021076A3 (fr) | Vaccins à base de matrice protéique et procédés de fabrication et d'administration de tels vaccins | |
WO2006126981A3 (fr) | Compositions et methodes destinees a la vaccination par voie muqueuse | |
WO2008039218A3 (fr) | Inhibiteurs de la tyrosine kinase de bruton | |
WO2007130493A3 (fr) | Combinaison adjuvante synergique d'anticorps agoniste cd40/interféron de type 1, conjugués contenant une telle combinaison et utilisation en tant qu'agent thérapeutique pour améliorer l'immunité cellulaire | |
WO2006072625A8 (fr) | Procedes et traitements combines anti-kir | |
WO2007147001A3 (fr) | Formulations lyophilisées d'anticorps anti-egfr | |
WO2008073448A3 (fr) | Formulations pharmaceutiques et leurs procédés de production | |
TW200612898A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same | |
WO2007095337A3 (fr) | formulation d'anticorps | |
WO2007047146A3 (fr) | Inhibiteurs de réplication virale | |
WO2005102392A3 (fr) | Methodes de traitement d'une infection a vih | |
TW200716157A (en) | Pharmaceutical formulations and methods of treatment using the same | |
DK1187629T3 (da) | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid | |
WO2008014979A3 (fr) | Acide nucléique de formule (i): gixmgn, ou(ii): cixmcn, en particulier en tant qu'agent/adjuvant immunostimulant | |
UA95238C2 (uk) | Імуногенна композиція | |
WO2007057763A3 (fr) | Oxyde nitrique utilisé comme agent antiviral, vaccin et adjuvant de vaccin | |
MA30065B1 (fr) | Vaccin | |
IL180572A0 (en) | Active ingredients for enhancing pathogen defense in plants, and methods of finding them | |
MA32819B1 (fr) | Vaccin combine notamment contre la coqueluche acellulaire | |
WO2007081896A3 (fr) | Compositions pharmaceutiques et méthodes de vaccination contre les candidoses disséminées et d'autres agents infectieux | |
AP1891A (en) | HIV immunogenic compositions and methods. | |
WO2009080715A3 (fr) | Vaccins anti-malaria |